


PHARMACEUTICAL 2017

Oncolix Inc. Rank 313 of 313





PHARMACEUTICAL 2017

Oncolix Inc. Rank 313 of 313

The relative strengths and weaknesses of Oncolix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncolix Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 8,850% points. The greatest weakness of Oncolix Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 16,637% points.

The company's Economic Capital Ratio, given in the ranking table, is -17,402%, being 16,985% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	1.7
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	226
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	104
Other Liabilities	0
Other Net Income	-4,702
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	10

Output Variable	Value in 1000 USD
Assets	1.7
Liabilities	226
Expenses	114
Stockholders Equity	-224
Net Income	-4,816
Comprehensive Net Income	-4,816
Economic Capital Ratio	-17,402%